Continuous subcutaneous infusion of compound oxycodone for the relief of dyspnea in patients with terminally ill cancer: a retrospective study
Related Experiment Video
Updated: May 21, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Masahiro Kawabata1, Keisuke Kaneishi
1The Palliative Care Unit, Tokyo Kosei-Nenkin Hospital, Tokyo, Japan. kawabata@tkn-hosp.gr.jp
Abstract:
Pain and dyspnea are the most prevalent and distressing symptoms in patients with terminally ill cancer. Evidences have accumulated for the effects of morphine on dyspnea, whereas little is known about the effects of oxycodone on dyspnea. We investigated the effectiveness of oxycodone for dyspnea in patients with terminally ill cancer. The injectable form of compound oxycodone (iOC) containing hydrocotarnine was administered continuously via subcutaneous route. We administered iOC to 136 patients. The effect on dyspnea was less conspicuous than pain, yet iOC was effective for dyspnea with varying degrees. None of the adverse effects observed were serious. These results suggest that continuous subcutaneous administration of oxycodone could be one of the reasonable alternatives in the management of dyspnea in patients with terminally ill cancer.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
IV Infusion to Oral Dosing: Conversion Methods
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
COPD: Management Using Bronchodilators and Corticosteroids
Drug Dosing: Obese Patients
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
